The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $9.89

Today's change+2.91 +41.69%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $9.89

Today's change+2.91 +41.69%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc Hits New 52-week High

ARIAD Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$2.91 or 41.69% to (U.S.)$9.89 and setting a new 52-week high. Over the last five days, shares have gained 49.17% and are currently 1.79% off of the 52-week high. Shares have outperformed the S&P 500 by 59.40% during the last year.

Key company metrics

  • Open(U.S.) $6.90
  • Previous close(U.S.) $6.98
  • High(U.S.) $10.07
  • Low(U.S.) $6.90
  • Bid / Ask-- / --
  • YTD % change+43.96%
  • Volume38,733,030
  • Average volume (10-day)7,029,676
  • Average volume (1-month)5,279,407
  • Average volume (3-month)3,621,036
  • 52-week range(U.S.) $4.90 to (U.S.) $10.07
  • Beta1.28
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.91
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-127.42%

Although this company's net profit margin is negative, it is above the industry average and implies that ARIAD Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue29246715
Total other revenue--------
Total revenue29246715
Gross profit29236614
Total cost of revenue0111
Total operating expense88747462
Selling / general / administrative49344034
Research & development39393328
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-59-50-7-47
Interest income (expense), net non-operating-4-4-4-4
Gain (loss) on sale of assets--------
Other--------
Income before tax-63-52-6-50
Income after tax-63-53-6-50
Income tax, total0000
Net income-63-53-6-50
Total adjustments to net income--------
Net income before extra. items-63-53-6-50
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-63-53-6-50
Inc. avail. to common incl. extra. items-63-53-6-50
Diluted net income-63-53-6-50
Dilution adjustment--------
Diluted weighted average shares189188187187
Diluted EPS excluding extraordinary itemsvalue per share-0.33-0.28-0.03-0.27
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.33-0.28-0.03-0.27